Peer-reviewed veterinary case report
Canine Osteosarcoma Treated by Post-Amputation Sequential Accelerated Doxorubicin and Carboplatin Chemotherapy: 38 Cases.
- Journal:
- Journal of the American Animal Hospital Association
- Year:
- 2016
- Authors:
- Frimberger, Angela E et al.
- Affiliation:
- and Animal Referral Hospital · Australia
- Species:
- dog
Plain-English summary
This study looked at 38 dogs with a type of bone cancer called appendicular osteosarcoma, which is a serious issue in veterinary medicine. The dogs had their affected limb amputated and then received a special chemotherapy treatment that was given more frequently than usual, but still expected to be safe. The average survival time for these dogs was about 317 days, with around 43% surviving for one year and about 14% for two years. The side effects were similar to those seen with standard treatments, and only a small number of dogs needed hospitalization for complications that were treatable. Overall, the results were comparable to other chemotherapy treatments for this type of cancer in dogs.
Abstract
Canine appendicular osteosarcoma is an important clinical problem in veterinary medicine. Current standard therapy includes amputation followed by chemotherapy, which improves outcomes; however the percentage of long-term survival is still relatively low at 15-20%. Established prognostic factors include serum alkaline phosphatase level, histologic grade, and lymphocyte and monocyte counts. We used a protocol with shorter inter-treatment intervals than standard, but which we expected to still be well-tolerated, based on drugs known to be active agents, with the aim of improving outcomes by increasing dose intensity. Thirty-eight dogs with confirmed appendicular osteosarcoma and no pulmonary metastases that underwent amputation followed by this chemotherapy protocol were retrospectively evaluated. The median survival time was 317 days and 1- and 2-yr survival percentages were 43.2% and 13.9%, respectively. Toxicity was comparable to that seen with other standard dose protocols, with 5.2% of dogs hospitalized for complications that resolved with supportive care and no chemotherapy-related mortality. Serum alkaline phosphatase level (normal or high) (p = 0.004) and whether or not chemotherapy was completed (p = 0.001) were found to significantly impact survival time on multivariate analysis. Outcomes were similar to those reported with most other published chemotherapy protocols for dogs with this disease.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/27008320/